title: Stereotactic conformal radiotherapy for pituitary adenomas: technique and preliminary experience.
abstract: OBJECTIVE
  Stereotactic conformal radiotherapy (SCRT) is a high precision technique of fractionated radiotherapy which ensures accurate delivery of radiation with reduction in the volume of normal tissue irradiated as compared to conventional external beam radiotherapy. We describe the technique and preliminary experience of SCRT in patients with residual and recurrent pituitary adenomas.
  
  
  METHODS
  Between February 1995 and March 1999, 22 patients (mean age: 45.3, range: 20-67 years) with residual or recurrent pituitary adenomas (13 nonfunctioning, nine secretory) were treated with SCRT. All were immobilized in a relocatable Gill-Thomas-Cosman (GTC) frame and tumour was localized on a postcontrast planning computerized tomography (CT) and MRI scan. The gross tumour volume (GTV) and the critical structures were outlined on contiguous 2-3 mm separated slices. A margin of 5 mm (12 patients) to 10 mm (10 patients) was grown around GTV in three-dimensions (3-D) to generate the planning target volume (PTV). The treatment was delivered by three (five patients) and four (17 patients) maximally separated conformal fixed fields with each field conformed to the shape of the tumour using customized lead alloy blocks (19 patients) or multileaf collimator (three patients). The patients were treated on a 6-MV linear accelerator to a dose of 45 Gy in 25 fractions (18 patients) and 50 Gy in 30 fractions (four patients).
  
  
  RESULTS
  The technique of SCRT has become a part of the routine work of the radiotherapy department. The treatment was well tolerated with minimal acute toxicity. One patient developed transient quadrantanopia 2 weeks after treatment with full recovery after a short course of corticosteroids. One patient had a transient visual deterioration 7 months after treatment due to cystic degeneration of the tumour which fully recovered following surgical decompression. Nine of the 15 patients presenting with visual impairment had improvement after treatment and the visual status remained stable in all others. One patient with acromegaly and one with a prolactinoma achieved normalization of elevated hormonal abnormality four and 10 months after SCRT, respectively. The remaining seven patients with a secretory adenoma had declining hormone levels at last follow-up. Newly initiated hormone replacement therapy was required in five patients. At a median follow-up of 9 months (range 1-44 months), the 1 and 2 year actuarial progression free and overall survival were 100%.
  
  
  CONCLUSIONS
  Stereotactic conformal radiotherapy is a high precision technique suitable for the treatment of pituitary adenomas requiring radiotherapy. Preliminary results suggest effective tumour control and low toxicity within the range expected for conventional external beam radiotherapy. While the technique is of potential benefit in reducing the volume of normal brain irradiated, the advantages in terms of sustained tumour control and reduced toxicity over conventional radiotherapy need to be demonstrated in long-term prospective studies.
authors.affiliation: Department of Physics, The Institute of Cancer Research and The Royal Marsden NHS Trust, London, UK.
authors.forename: R
authors.initials: R
authors.lastname: Jalali
authors.forename: M
authors.initials: M
authors.lastname: Brada
authors.forename: J R
authors.initials: JR
authors.lastname: Perks
authors.forename: A P
authors.initials: AP
authors.lastname: Warrington
authors.forename: D
authors.initials: D
authors.lastname: Traish
authors.forename: L
authors.initials: L
authors.lastname: Burchell
authors.forename: H
authors.initials: H
authors.lastname: McNair
authors.forename: D G
authors.initials: DG
authors.lastname: Thomas
authors.forename: S
authors.initials: S
authors.lastname: Robinson
authors.forename: D G
authors.initials: DG
authors.lastname: Johnston
mesh_terms: D000236:Adenoma / Q000378:metabolism / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D005260:Female; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy*; D018365:Neoplasm, Residual / Q000532:radiotherapy; D010911:Pituitary Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D015175:Prolactinoma / Q000532:radiotherapy; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000379:methods*
chemical_list: D013006:Growth Hormone